R. Love

发表

Cigarette smoking and mortality risk in people with schizophrenia.

D. Kelly, R. McMahon, H. Wehring, 2011, Schizophrenia bulletin.

Clozapine underutilization and discontinuation in African Americans due to leucopenia.

Julie Kreyenbuhl, Deanna L Kelly, R. Conley, 2007, Schizophrenia bulletin.

Addressing Barriers to Clozapine Underutilization: A National Effort.

D. Kelly, R. Love, O. Freudenreich, 2017, Psychiatric services.

Atypical antipsychotic use in a state hospital inpatient adolescent population.

R. Conley, D. Kelly, R. McMahon, 2004, Journal of child and adolescent psychopharmacology.

Rehospitalization Risk with Second-Generation and Depot Antipsychotics

R. Conley, D. Kelly, R. McMahon, 2003, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months.

R. Conley, D. Kelly, R. Love, 1998, Journal of child and adolescent psychopharmacology.

The Family Value of Information, Community Support, and Experience Study: Rationale, Design, and Methods of a “Family-Centered” Research Study

J. Schiffman, H. Wehring, R. Love, 2015, The Journal of nervous and mental disease.

Blood Draw Barriers for Treatment with Clozapine and Development of a Point-of-Care Monitoring Device.

Eunkyoung Kim, G. Payne, D. Kelly, 2015, Clinical schizophrenia & related psychoses.

Novel versus Conventional Antipsychotic Drugs

R. Love, 1996, Pharmacotherapy.

Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine.

J J Bartko, R. Conley, D. Kelly, 1999, The American journal of psychiatry.

A dose-outcome analysis of risperidone.

R. Conley, D. Kelly, R. Love, 1999, The Journal of clinical psychiatry.

Novel Factor-Based Symptom Scores in Treatment Resistant Schizophrenia: Implications for Clinical Trials

R. Conley, D. Kelly, R. Love, 2002, Neuropsychopharmacology.

Pharmacology and clinical experience with risperidone

R. Love, M. Nelson, 2000, Expert opinion on pharmacotherapy.

Comparison of clozapine use in Maryland and in Victoria, Australia.

R. Conley, D. Kelly, R. Love, 2005, Psychiatric services.

Clozapine utilization and outcomes by race in a public mental health system: 1994-2000.

R. Conley, D. Kelly, R. Love, 2006, The Journal of clinical psychiatry.

Clozapine in Reducing Aggression and Violence in Forensic Populations

D. Kelly, S. Feldman, R. Love, 2018, Psychiatric Quarterly.

A guide for managing acute aggressive behavior of youths in residential and inpatient treatment facilities.

R. Love, M. Riddle, S. dosReis, 2003, Psychiatric services.

Clinical characteristics of heavy and non-heavy smokers with schizophrenia

D. Kelly, H. Wehring, Kristen M. Mackowick, 2012, Schizophrenia Research.

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.

R. Conley, R. Love, J. Bartko, 1998, The American journal of psychiatry.

Anti-aggressive effects of clozapine in involuntarily committed black patients with severe mental illness

D. Kelly, H. Wehring, R. Love, 2022, Schizophrenia Research.

Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving management

D. Kelly, R. Love, 2019, The mental health clinician.

Comparison of Clozapine Response for Inpatients in the Research Setting Versus Routine Clinical Practice

R. Conley, D. Kelly, D. Boggs, 2008, Psychiatric Quarterly.

Leadership: The Nexus Between Challenge and Opportunity: Reports of the 2002–03 Academic Affairs, Professional Affairs, and Research and Graduate Affairs Committees

R. Love, W. Millard, R. Bridges, 2003 .

Urine testing for antipsychotics: a pilot trial for a method to determine detection levels

D. Kelly, H. Wehring, S. Feldman, 2015, Human psychopharmacology.

Risperidone, Quetiapine, and Fluphenazine in the Treatment of Patients With Therapy-Refractory Schizophrenia

R. Conley, D. Kelly, S. Feldman, 2005, Clinical neuropharmacology.

An Evidence-Based Approach to Optimizing the Management of Psychotic Disorders in the Long-Term Care Setting

R. Love, D. Sultzer, W. Faison, 2006 .

Effects of Cigarette Smoking and Clozapine Treatment on 20-Year All-Cause & Cardiovascular Mortality in Schizophrenia

D. Kelly, H. Wehring, R. Love, 2019, Psychiatric Quarterly.

Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.

R. Conley, D. Kelly, R. Love, 2008, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Strategies for increasing treatment compliance: the role of long-acting antipsychotics.

R. Love, 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Assessment of capacity to give consent to research participation: state-of-the-art and beyond.

R. Conley, R. Love, R R Conley, 1998, Journal of health care law & policy.

Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone

D. Kelly, H. Wehring, S. Feldman, 2009, Schizophrenia Research.

Improving clozapine utilization will require continued advocacy, drug sponsor interest, and FDA support to address REMS issues

R. Love, J. Leung, M. Ehret, 2023, Expert review of clinical pharmacology.

Chapter 12. Ethical and Legal Issues Pertinent to Public Health Pharmacy

R. Love, P. Ballard, Linda Bethman, 2010 .

Long-acting risperidone injection.

R. Love, R. Conley, 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders.

D. Kelly, H. Wehring, Kristen M. Mackowick, 2012, Journal of psychiatric research.

Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.

R. Conley, D. Kelly, H. Wehring, 2010, The Journal of clinical psychiatry.

Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations.

D. Kelly, R. Love, 2001, Psychopharmacology bulletin.

Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone.

R. Conley, R. Love, D. B. Moore, 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.

R. Conley, D. Kelly, R. Love, 2003, The Journal of clinical psychiatry.

Clozapine and neutrophil response in patients of African descent: A six-month, multinational, prospective, open-label clinical trial

D. Kelly, H. Wehring, R. Love, 2023, Schizophrenia Research.